Alfred Sandrock - Feb 9, 2024 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Role
President and CEO, Director
Signature
/s/ Scott MacDonald, as Attorney-in-Fact for Alfred Sandrock
Stock symbol
VYGR
Transactions as of
Feb 9, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 04:59 PM
Previous filing
Apr 5, 2023
Next filing
Feb 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYGR Common Stock Award $0 +130K +59.64% $0.00 348K Feb 9, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYGR Stock Option (Right to Buy) Award $0 +260K $0.00 260K Feb 9, 2024 Common Stock 260K $7.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of common stock issuable under an aggregate of 130,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
F2 Includes 3,369 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.
F3 This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.